Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.
Also called NCT01375751
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 168 participants
- Sponsor
- Registry
-
NCT01375751
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01375751. Randomized; quadruple masking; primary purpose treatment. Start 2011-08-02 (actual); primary completion 2012-05-16 (actual). Results posted on 2015-09-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
- Acronym
- RUTHERFORD
- Condition
- Hypercholesterolemia, Familial
- Intervention (Biological)
- Evolocumab
- Intervention (Biological)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01375751- Content hash
693cfb3ea15746aca437644d3a18e3c13f4a5e2b73e83e4a8497cb98fc043b43